Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy

Mark A. Stacy, Harald Murck, Kurt Kroenke

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: The duration of clinical control of motor symptoms of Parkinson disease (PD) treated with levodopa/carbidopa preparations eventually starts to shorten, a phenomenon known as end-of-dose "wearing off." The involvement of core nonmotor symptoms of "wearing off" (depressed mood, pain/aching, anxiety, and cloudy/slowed thinking) is not well understood. Methods: A post hoc analysis from a study to validate the self-rated 9-item, Wearing-Off Questionnaire (WOQ-9), which was designed to identify motor and nonmotor symptoms of "wearing off" in PD patients, was performed to compare the frequency and sensitivity of motor and nonmotor symptoms of "wearing off" from dopaminergic therapy. Results: Analysis of responses to the WOQ-9 from 216 PD patients found that individual nonmotor symptoms were reported by 25% to 50% and motor symptoms by 55% to 80% of patients. Individual nonmotor symptoms improved following the next dose of dopaminergic therapy in 43% to 53% of the patients who presented with such symptoms, whereas motor symptoms improved in 48% to 66% of the cases, suggesting both types of symptoms respond to dopaminergic therapies. Conclusion: Nonmotor symptoms of PD appear sensitive to dopaminergic treatment. These symptoms resemble those seen with depressive, anxiety, and somatoform disorders suggesting potential shared mechanisms as well as possible treatment implications.

Original languageEnglish
Pages (from-to)57-61
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume34
Issue number1
DOIs
StatePublished - Jan 20 2010

Fingerprint

Parkinson Disease
Therapeutics
Somatoform Disorders
Depressive Disorder
Anxiety Disorders
Anxiety
Pain

Keywords

  • Dopamine
  • Dyskinesia
  • Motor fluctuations
  • Nonmotor
  • Somatization
  • Wearing off

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. / Stacy, Mark A.; Murck, Harald; Kroenke, Kurt.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 34, No. 1, 20.01.2010, p. 57-61.

Research output: Contribution to journalArticle

@article{07da5afea5594929999178685d08f17d,
title = "Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy",
abstract = "Background: The duration of clinical control of motor symptoms of Parkinson disease (PD) treated with levodopa/carbidopa preparations eventually starts to shorten, a phenomenon known as end-of-dose {"}wearing off.{"} The involvement of core nonmotor symptoms of {"}wearing off{"} (depressed mood, pain/aching, anxiety, and cloudy/slowed thinking) is not well understood. Methods: A post hoc analysis from a study to validate the self-rated 9-item, Wearing-Off Questionnaire (WOQ-9), which was designed to identify motor and nonmotor symptoms of {"}wearing off{"} in PD patients, was performed to compare the frequency and sensitivity of motor and nonmotor symptoms of {"}wearing off{"} from dopaminergic therapy. Results: Analysis of responses to the WOQ-9 from 216 PD patients found that individual nonmotor symptoms were reported by 25{\%} to 50{\%} and motor symptoms by 55{\%} to 80{\%} of patients. Individual nonmotor symptoms improved following the next dose of dopaminergic therapy in 43{\%} to 53{\%} of the patients who presented with such symptoms, whereas motor symptoms improved in 48{\%} to 66{\%} of the cases, suggesting both types of symptoms respond to dopaminergic therapies. Conclusion: Nonmotor symptoms of PD appear sensitive to dopaminergic treatment. These symptoms resemble those seen with depressive, anxiety, and somatoform disorders suggesting potential shared mechanisms as well as possible treatment implications.",
keywords = "Dopamine, Dyskinesia, Motor fluctuations, Nonmotor, Somatization, Wearing off",
author = "Stacy, {Mark A.} and Harald Murck and Kurt Kroenke",
year = "2010",
month = "1",
day = "20",
doi = "10.1016/j.pnpbp.2009.09.023",
language = "English",
volume = "34",
pages = "57--61",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy

AU - Stacy, Mark A.

AU - Murck, Harald

AU - Kroenke, Kurt

PY - 2010/1/20

Y1 - 2010/1/20

N2 - Background: The duration of clinical control of motor symptoms of Parkinson disease (PD) treated with levodopa/carbidopa preparations eventually starts to shorten, a phenomenon known as end-of-dose "wearing off." The involvement of core nonmotor symptoms of "wearing off" (depressed mood, pain/aching, anxiety, and cloudy/slowed thinking) is not well understood. Methods: A post hoc analysis from a study to validate the self-rated 9-item, Wearing-Off Questionnaire (WOQ-9), which was designed to identify motor and nonmotor symptoms of "wearing off" in PD patients, was performed to compare the frequency and sensitivity of motor and nonmotor symptoms of "wearing off" from dopaminergic therapy. Results: Analysis of responses to the WOQ-9 from 216 PD patients found that individual nonmotor symptoms were reported by 25% to 50% and motor symptoms by 55% to 80% of patients. Individual nonmotor symptoms improved following the next dose of dopaminergic therapy in 43% to 53% of the patients who presented with such symptoms, whereas motor symptoms improved in 48% to 66% of the cases, suggesting both types of symptoms respond to dopaminergic therapies. Conclusion: Nonmotor symptoms of PD appear sensitive to dopaminergic treatment. These symptoms resemble those seen with depressive, anxiety, and somatoform disorders suggesting potential shared mechanisms as well as possible treatment implications.

AB - Background: The duration of clinical control of motor symptoms of Parkinson disease (PD) treated with levodopa/carbidopa preparations eventually starts to shorten, a phenomenon known as end-of-dose "wearing off." The involvement of core nonmotor symptoms of "wearing off" (depressed mood, pain/aching, anxiety, and cloudy/slowed thinking) is not well understood. Methods: A post hoc analysis from a study to validate the self-rated 9-item, Wearing-Off Questionnaire (WOQ-9), which was designed to identify motor and nonmotor symptoms of "wearing off" in PD patients, was performed to compare the frequency and sensitivity of motor and nonmotor symptoms of "wearing off" from dopaminergic therapy. Results: Analysis of responses to the WOQ-9 from 216 PD patients found that individual nonmotor symptoms were reported by 25% to 50% and motor symptoms by 55% to 80% of patients. Individual nonmotor symptoms improved following the next dose of dopaminergic therapy in 43% to 53% of the patients who presented with such symptoms, whereas motor symptoms improved in 48% to 66% of the cases, suggesting both types of symptoms respond to dopaminergic therapies. Conclusion: Nonmotor symptoms of PD appear sensitive to dopaminergic treatment. These symptoms resemble those seen with depressive, anxiety, and somatoform disorders suggesting potential shared mechanisms as well as possible treatment implications.

KW - Dopamine

KW - Dyskinesia

KW - Motor fluctuations

KW - Nonmotor

KW - Somatization

KW - Wearing off

UR - http://www.scopus.com/inward/record.url?scp=73649090347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649090347&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2009.09.023

DO - 10.1016/j.pnpbp.2009.09.023

M3 - Article

VL - 34

SP - 57

EP - 61

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -